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ABSTRACT
Enterobacterial isolates producing CTX-M b-lactamases have recently emerged worldwide in the
community and hospital settings. Because of the signiﬁcant public health implications, the spread of
organisms producing CTX-M enzymes merits close monitoring with enhanced surveillance efforts. A
molecular diagnostic assay using two different sets of primers simultaneously for the detection of all
blaCTX-M-like b-lactamase genes was developed. This assay repeatedly demonstrated 100% sensitivity,
speciﬁcity and positive and negative predictive values for detecting different CTX-M enzymes in
well-characterised strains that included producers of VEB-, TEM- and SHV-type extended-spectrum
b-lactamases (ESBLs) and plasmid-mediated AmpC enzymes. The majority (132 ⁄ 240; 55%) of
ESBL-producing enterobacterial isolates recovered in the Calgary Health Region during 2003 and
2004 were positive for blaCTX-M genes, including 81 (61%) positive for the CTX-M-9 group, 49 (37%) for
the CTX-M-1 group, and two (2%) for the CTX-M-2 group. The CTX-M-speciﬁc PCR assay was
reproducible and easy to use. It can be introduced in a clinical or reference laboratory to track and
monitor the spread of organisms producing CTX-M enzymes in the community and hospital settings.
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INTRODUCTION
Enterobacteriaceae, especially Klebsiella spp. pro-
ducing extended-spectrum b-lactamases (ESBLs)
belonging to the SHV and TEM groups, have been
recognised since the 1980s as a major cause of
hospital-acquired infections [1]. More recently,
Enterobacteriaceae (mostly Escherichia coli) pro-
ducing novel ESBLs, e.g., the CTX-M enzymes,
have emerged within the hospital and community
settings as an important cause of urinary tract
infection [2,3]. The CTX-M b-lactamases, of which
there are now more than 40 types, can be divided
into ﬁve groups based on their amino-acid iden-
tities [4]: the CTX-M-1 group (including CTX-M-1,
-3, -10, -12, -15, -28 and -30, and FEC-1); the
CTX-M-2 group (including CTX-M-2, -4, -5, -6, -7
and -20, and Toho-1); the CTX-M-8 group (inclu-
ding CTX-M-8); the CTX-M-9 group (including
CTX-M-9, -13, -14, -16, -17, -19, -21, -24 and -27,
and Toho-2); and the CTX-M-25 group (including
CTX-M-25 and -26).
Surveys from several countries, e.g., Canada
[5,6], Spain [7–9], France [10], Korea [11] and the
UK [12], have shown that CTX-M-producing
Esch. coli strains, isolated from hospital and com-
munity settings, often exhibit co-resistance to
trimethoprim–sulphamethoxazole, tetracycline,
gentamicin and ciproﬂoxacin. Woodford et al.
[12] identiﬁed an epidemic clone of Esch. coli
producing CTX-M-15 that had become widely
distributed throughout the UK [12], while a
Canadian study described a CTX-M-14-producing
strain of Esch. coli that was the cause of a
community-wide clonal outbreak of urinary tract
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infection during 2000 and 2001 [13]. Similar
ﬁndings involving Esch. coli strains producing
CTX-M-9 and CTX-M-14 have been reported from
Spain [14,15]. The signiﬁcant public health impli-
cations, including the treatment of community-
acquired urinary tract infection, mean that the
spread of organisms producing ESBLs (partic-
ularly CTX-M enzymes) merits close monitoring
with enhanced surveillance, and efforts should be
made to prevent the spread of organisms produ-
cing these enzymes within the hospital and
community settings.
Several studies have described molecular
approaches that allow screening of ESBL-positive
organisms for the presence of different CTX-M
genes. Ampliﬁcation and sequencing of blaCTX-M
genes is time-consuming and expensive, and
involves multiple reactions with different primers
for each speciﬁc gene [16,17]. Some studies have
utilised ampliﬁcation of a universal DNA frag-
ment speciﬁc for most of the different groups of
CTX-M b-lactamases [18,19], and a multiplex PCR
that differentiates between the ﬁve CTX-M phy-
logenetic groups has also been described [20].
Unfortunately, none of these methods has been
veriﬁed extensively or validated in routine use.
Therefore, the present study was designed to
develop, validate and verify a molecular detection
assay for the simultaneous detection of strains
carrying different types of blaCTX-M b-lactamase
genes, and to investigate the extent to which
genes encoding these enzymes were present
among ESBL-producing isolates of Enterobacteri-
aceae from clinical specimens in the Calgary
Health Region, Canada, during 2003 and 2004.
MATERIALS AND METHODS
Bacteria
Consecutive non-duplicate isolates of all Enterobacteriaceae
(one per patient; n = 240) collected at Calgary Laboratory
Services during January 2003 and December 2004 were used in
this study. These organisms were screened for ESBL produc-
tion and then investigated for the presence of CTX-M
b-lactamases. Isolates were identiﬁed to the species level with
the Vitek AMS (bioMe´rieux Vitek Systems Inc., Hazelwood,
MO, USA). Strains (n = 28) with well-characterised b-lacta-
mases were used as positive and negative controls for the
veriﬁcation and validation of the PCR assay (Table 1). An
additional group (n = 14) of AmpC-producing Esch. coli
strains, isolated recently in the Calgary Health Region, were
also included; these isolates were resistant to cefoxitin,
cefotaxime and ceftazidime, and tested positive for AmpC
cephalosporinases using the combination of the AmpC
Table 1. Control strains producing
well-characterised b-lactamases
Strain Organism b-Lactamase Groupa
Primers
Reference or
sourceCTXMA1 ⁄A2b CTX825F ⁄Rb
CF2 Enterobacter cloacae CTX-M-1 1 + – [31]
Rio-4 Proteus mirabilis CTX-M-2 2 + – [32]
VER-1 Ent. cloacae CTX-M-3 1 + – [31]
Cfr2525 ⁄ 96 Citrobacter freundii CTX-M-3 1 + – [33]
34 Salmonella typhimurium CTX-M-5 2 + – [34]
Rio-3 Enterobacter aerogenes CTX-M-8 8 – + [32]
785D Escherichia coli CTX-M-9 9 + – [35]
EC97 ⁄ 38582 Esch. coli CTX-M-10 1 + – [36]
EC984167 Esch. coli CTX-M-14 9 + – [37]
CF1 Esch. coli CTX-M-14 9 + – [31]
Eco3553 ⁄ 98 Esch. coli CTX-M-15 1 + – [38]
N00-0666 Esch. coli CTX-M-15 1 + – [39]
Rio-6 Esch. coli CTX-M-16 9 + – [40]
BM4493 Klebsiella pneumoniae CTX-M-17 9 + – [41]
ILT-2 K. pneumoniae CTX-M-18 9 + – [42]
ILT-3 K. pneumoniae CTX-M-19 9 + – [42]
ESBL530 Esch. coli CTX-M-25 25 – + [43]
Cf29 C. freundii CTX-M-30 1 + – [44]
CT1 Esch. coli Toho-1 2 + – [45]
1A Esch. coli VEB-1 – – – [46]
S1 Esch. coli SHV-2 – – – [47]
S2 Esch. coli SHV-7 – – – [47]
T1 Esch. coli TEM-3 – – – [47]
T4 Esch. coli TEM-10 – – – [47]
T5 Esch. coli TEM-50 – – – [47]
A1 Esch. coli MOX-1 – – – [47]
A2 Esch. coli FOX-1 – – – [47]
A3 Salmonella spp. CMY-2 – – – [48]
C1 Ent. cloacae NMC-A – – – [47]
C2 K. pneumoniae KPC-1 – – – [47]
aGroup 1 includes CTX-M-1, -3, -10, -11, -12, -15, -22, -23, -28, -29 and -30; group 2 includes CTX-M-2, -4, -5, -6, -7
and -20, and Toho-1; group 8 includes CTX-M-8; group 9 includes CTX-M-9, -13, -14, -16, -17, -18, -19, -21 and -27,
and Toho-2; and group 25 includes CTX-M-25 and -26.
bPCR primers for CTX-M groups (see Materials and methods).
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b-lactamase inhibitor Syn2190 and cefotetan disks, as des-
cribed previously [21].
Antimicrobial susceptibility testing
MICs of piperacillin–tazobactam, imipenem, gentamicin, to-
bramycin, trimethoprim–sulphamethoxazole and ciproﬂoxacin
were determined using the Vitek AMS. Throughout this study,
results were interpreted using CLSI (NCCLS) criteria for broth
dilution [22]. The quality control strains used for this part of
the study were Esch. coli ATCC 25922 and Esch. coli
ATCC 35218.
Screening for and conﬁrmation of ESBLS
The presence of ESBLs in clinical isolates of Esch. coli and
Klebsiella spp. was investigated using the CLSI (NCCLS)
criteria for ESBL screening and disk conﬁrmation tests [22].
Clinical isolates of Enterobacteriaceae other than Esch. coli and
Klebsiella spp. were investigated for ESBL production using the
modiﬁed double-disk test [23]. Disks for ESBL conﬁrmation
tests were obtained from Oxoid (Nepean, Ontario, Canada).
Klebsiella pneumoniae ATCC 700603 and Esch. coli ATCC 25922
were used as positive and negative controls, respectively.
b-Lactamase gene identiﬁcation
Template DNA was prepared from an overnight culture (18–
24 h) on a Mueller–Hinton plate. Two colonies were resus-
pended in 100 lL of distilled water and the cells were lysed by
heating at 95C for 10 min. Cellular debris was removed by
centrifugation at 15 000 g for 2 min, and the supernatant was
used as a source of template DNA for ampliﬁcation. PCR for
the simultaneous detection of blaCTXM b-lactamase genes was
performed on a 9700 thermal cycler (Applied Biosystems,
Norwalk, CT, USA) with Platinium Taq DNA polymerase kits
and a 2 mM dNTP mix (Invitrogen, Carlsbad, CA, USA).
Reaction mixtures comprised 10 mM Tris-HCl (pH 8.3),
50 mM KCl, 1.5 mM MgCl2, 0.25 mM dATP, dGTP and dCTP
(Invitrogen), 0.75 mM dUTP (Roche Diagnostics, Laval, Que-
bec, Canada), 0.1 lM CTX-MA1, CTX-MA2, CTX825-F and
CTX-825R primers (see below), 0.125 lM rrs-1 primer and rrs-2
primer [24], 0.125 U of uracil-N-glycosylase and 2.5 U of
Platinum Taq, in a total volume of 22 lL. Following the
addition of 3 lL of sample lysate to the reaction mixture, the
PCR program comprised 10 min at 37C and 6 min at 94C,
followed by 30 cycles of 92C for 1 min, 55C for 1 min and
72C for 1 min, followed by 72C for 7 min. The PCR products
were then stored at 4C until analysis (0.1 · volume) by
electrophoresis in agarose 1.5% w ⁄v gels in 0.5 · TBE buffer
(1 · TBE is 89 mM Tris, 89 mM boric acid, 2 mM EDTA). The
gels were stained with ethidium bromide and the PCR
products were visualised with UV light.
Primers
The primers used for PCR ampliﬁcation of CTX-M types from
groups CTX-M-1, CTX-M-2 and CTX-M-9 were CTX-MA1 (5¢-
SCSATGTGCAGYACCAGTAA) and CTX-MA2 (5¢-CCGCRA-
TATGRTTGGTGGTG), yielding a 450-bp amplicon [25] (S = G
or C; Y = C or T; R = A or G). These are degenerate primers
that are a mixture of different primers in equal amounts to
ensure optimal binding capacity. The primers used for PCR
ampliﬁcation of CTX-M types from groups CTX-M-8 and CTX-
M-25 were CTX825F (5¢-CGCTTTGCCATGTGCAGCACC) and
CTX825R (5¢-GCTCAGTACGATCGAGCC), yielding a 307-bp
amplicon [26].
Veriﬁcation of the assay
The accuracy (i.e., clinical sensitivity and speciﬁcity) of the test
was investigated using strains with well-characterised resist-
ance mechanisms (Table 1) as described previously [26].
Validation of the assay
The performance of the assay was evaluated over a period of
3 months [27], including the addition of a 320-bp internal
control (16S rRNA, rrs) to the reaction mixture [24], and the
repeated testing of well-characterised strains producing
known CTX-M b-lactamases, using different personnel and
ampliﬁcation instruments, including a 9800 Thermal Cycler
(Applied Biosystems). Results for the clinical isolates were
validated by testing all isolates that gave negative results with
the duplex CTX-M PCR by analytical isoelectric focusing
(aIEF) and PCRs for blaTEM and blaSHV [28], while positive
isolates were further tested by aIEF and CTX-M group-speciﬁc
primers [26].
RESULTS
Veriﬁcation of the assay for blaCTX-M genes
The primers used in this study were veriﬁed
using DNA templates prepared from control
strains with speciﬁc CTX-M b-lactamases or
strains producing b-lactamases other than CTX-
M enzymes (Table 1). The CTX-MA1 ⁄A2 primers
showed 100% sensitivity, speciﬁcity and positive
and negative predictive values for detecting CTX-
M-1, -2, -3, -5, -9, -10, -14, -15, -16, -17, -19 and -30,
while the CTX825F ⁄R primers showed 100%
sensitivity, speciﬁcity and positive and negative
predictive values for detecting CTX-M-8 and -25.
Both sets of primers were used simultaneously
and did not cross-react with strains producing
VEB-1, TEM-3, -10 and -52, SHV-2, -7 and -12,
KPC-1, NMC-A, MOX-1, CMY-2 and FOX-1
(Table 1). The same results were obtained with
different species of Enterobacteriaceae (Tables 1
and 2).
Validation of the assay for blaCTX-M genes
The assay procedure was validated by adding the
rrs internal control and by repeating the proce-
dure ﬁve times on consecutive days with the
control strains shown in Fig. 1. To ensure that the
assay would be suitable for routine diagnostic
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use, the procedure was repeated an additional
ﬁve times using different thermocyclers on dif-
ferent days with different personnel. The assay
performed accurately on each occasion.
Clinical bacterial isolates
Of 240 ESBL-producing Enterobacteriaceae isola-
ted during the study period, 217 (90%) were
Esch. coli, 12 (5%) were Klebsiella spp., six (3%)
were Salmonella spp., two (1%) each were
Citrobacter freundii and Enterobacter cloacae,
respectively, and one was Citrobacter koseri. The
majority of isolates (211; 88%) were recovered
from urine, 14 (6%) from blood, six (3%) from
stool, and the remaining nine (4%) from miscel-
laneous other specimens. Of the 240 clinical
isolates included in this study, 132 (55%) were
resistant to trimethoprim–sulphamethoxazole, 20
(8%) to piperacillin–tazobactam, 95 (40%) to
tobramycin, 98 (41%) to gentamicin, and 120
(50%) to ciproﬂoxacin. No resistance to imipe-
nem was detected.
The 240 clinical isolates of Enterobacteriaceae
that were positive for ESBL production were
examined by PCR for the presence of blaCTX-M
genes. Of these, 132 (55%) were positive for
blaCTX-M genes, of which 124 were Esch. coli, seven
were Klebsiella spp. and one was Ent. cloacae.
When the 132 positive clinical isolates were fur-
ther tested with CTX-M group-speciﬁc primers,
81 (61%) were positive for the CTX-M-9 group, 49
(37%) were positive for the CTX-M-1 group, and
two (2%) were positive for the CTX-M-2 group
(Table 2). IEF showed that CTX-M-9 group en-
zymes had pIs of 8.0 and 8.1, the CTX-M-1 group
had pIs of 8.4 and 8.9, and the CTX-M-2 group
had a pI of 7.8.
Isolates (n = 108) belonging to the CTX-M-
negative group produced different cefotaxime-
hydrolysing b-lactamases, with pIs of 8.2–5.4 that
were suggestive of TEM- and SHV-type ESBLs.
PCR with blaTEM-speciﬁc primers ampliﬁed a 971-
bp fragment from isolates with TEM-like ESBLs,
while blaSHV-speciﬁc primers ampliﬁed an 885-bp
fragment from isolates with SHV-like ESBLs.
Analytical IEF of the AmpC-producing isolates
(n = 14) showed that all of these isolates pro-
duced enzymes with a pI of >9.0 that were
inhibited by cloxacillin when using the IEF
overlay technique, which is characteristic of
AmpC-type cephalosporinases [28]. Three isolates
Table 2. Group-speciﬁc CTX-M
b-lactamases detected using group-
speciﬁc primers [26] among recent
clinical isolates of CTX-M-positive
Enterobacteriaceae
Speciesa n
CTX-M-1
Groupb
CTX-M-2
Groupb
CTX-M-9
Groupb
CTX-M-8
Groupb
CTX-M-25
Groupb
Escherichia coli 124 47 (38%) 2 (2%) 75 (60%) 0 0
Klebsiella spp. 7 1 (14%) 0 6 (86%) 0 0
Enterobacter cloacae 1 1 (100%) 0 0 0 0
aPositive with the CTX-M PCR assay.
bGroup 1 includes CTX-M-1, -3, -10, -11, -12, -15, -22, -23, -28, -29 and -30; group 2 includes CTX-M-2, -4, -5, -6, -7
and -20, and Toho-1; group 8 includes CTX-M-8; group 9 includes CTX-M-9, -13, -14, -16, -17, -18, -19, -21 and -27,
and Toho-2; and group 25 includes CTX-M-25 and -26.
H N7N6N5N4P5 L P4P3P2P1 LN3N2 N1
500 bp
300 bp
rrs
Fig. 1. PCR assay for the detection
of blaCTX-M genes. Lanes: L, 100-bp
ladder; H, distilled water; N1, T1
(TEM-1); N2, T4 (TEM-10); N3, A1
(MOX-1); P1, CF2 (CTX-M-1); P2,
Rio-4 (CTX-M-2); P3, Rio-3 (CTX-M-
8); P4, CF1 (CTX-M-14); P5, ESBL530
(CTX-M-25); N4, S1 (SHV-2); N5, T1
(TEM-3); N6, A1 (MOX-1); and N7,
A2 (KPC-1). rrs indicates the 16S
rRNA internal control. Speciﬁc mar-
ker sizes in base pairs are shown on
the left. More details of the individ-
ual strains are given in Table 1.
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produced an additional b-lactamase with a pI of
8.1, and two isolates produced a b-lactamase with
a pI of 8.9. The duplex PCR ampliﬁed a 450-bp
amplicon from these ﬁve isolates; three (pI 8.1)
were positive with the CTX-M-9 group-speciﬁc
primers, and two (pI 8.9) were positive with the
CTX-M-1 group-speciﬁc primers. The remaining
nine AmpC-producing Esch. coli isolates were
negative for blaCTX-M genes.
DISCUSSION
The recent emergence of isolates producing CTX-
M variants capable of hydrolysing ceftazidime, as
well as cefotaxime, with high efﬁciency has
rendered their phenotypic recognition extremely
difﬁcult. Among those variants are the CTX-M-15,
CTX-M-16, CTX-M-19 and CTX-M-27 enzymes
[4]. Of the recent clinical isolates positive for
blaCTX-M genes included in the present study, 42
(32%) of 132 had increased ceftazidime MICs,
conﬁrming that the phenotypic identiﬁcation of
CTX-M-producing organisms is not a reliable
approach. The usefulness of the PCR test, and
probably other CTX-M detection methods, was
also evident for AmpC-producing Esch. coli har-
bouring CTX-M-type b-lactamases.
Molecular methods that include simple and
multiplex PCR, real-time PCR, DNA sequencing,
and various hybridisation-based techniques, are
now used widely in academia and in reference
laboratories for the detection of bacteria produ-
cing ESBLs [29]. Molecular methods have advan-
tages over phenotypic tests in that they accurately
and rapidly detect resistant genes and, by deﬁ-
ning the precise genetic basis of the resistance
mechanism, provide information valuable for
reaching decisions concerning the early introduc-
tion of targeted infection control practices [30].
Molecular detection of antibiotic resistance has
the potential to impact directly on patient care,
but the majority of in-house tests lack proper
veriﬁcation and validation for routine use in a
clinical laboratory [27]. The PCR described in the
present study has been validated for the simulta-
neous detection of the different groups of CTX-M
enzymes, takes c. 6 h to complete, and can be
performed by any microbiologist with some
molecular experience. The technique is therefore
suitable for use in clinical or reference laboratories
to screen, track and monitor the spread of large
numbers of organisms producing CTX-M
enzymes from the community and hospital set-
tings in real-time. All positive isolates can then be
further divided into the ﬁve CTX-M phylogenetic
groups using multiplex PCR [20] or group-speci-
ﬁc primers [26]. This will ensure the early recog-
nition of an outbreak involving organisms
producing CTX-M enzymes and the timely intro-
duction of appropriate infection control proce-
dures. The majority (55%) of ESBL-producing
Enterobacteriaceae isolated recently from the
CHR was positive for blaCTXM enzymes, which
emphasises the current emergence and spread of
CTX-M enzymes among Enterobacteriaceae in
this region. It is hoped that the present study
will provide a benchmark for the veriﬁcation and
validation of new in-house diagnostic molecular
assays before their introduction into clinical
microbiology laboratories.
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